Physicians feel positive about how Patient Support Programs (PSPs) have evolved in the past two years – especially in terms of responsiveness and the expertise of individuals working on PSPs. The main unmet needs at this time remain the range of service hours and the availabilityof nurses remotely (either by phone or virtually). Many specialists believe that biosimilar PSP providers have struggled more than originator drug PSPs since the onset of the pandemic – mainly because of they do not have as many employees and offer a smaller range of services.
Patient Support Programs (PSPs) play a significant role in ensuring that patients have the best possible experience during their journey – especially in specialty therapeutic areas where treatments tend to be more expensive. The COVID-19 pandemic has made it more challenging for patients to access support and services for their medical conditions. This has put additional pressure on company-sponsored PSPs to further enhance their offerings to help patients in the best way possible. PSPs have become increasingly important for patients since the onset of the COVID-19 pandemic and as a result now have an even more significant influence on physicians’ treatment selection process.
The COVID-19 vaccination campaign is underway in Canada. However, the pandemic has significantly altered HCPs’ practices to date. These changes have impacted workloads, patient assessments, and interactions with pharma. A year into the pandemic, a national COVID-19 vaccination campaign is underway. This begs the question, how are Canadian HCPs doing today? What do they foresee moving forward? Our latest short survey presents the current state of HCPs’ practices in Canada and their assessment of the government’s management of COVID-19.
Quelles sont les conférences auxquelles les médecins sont le plus susceptibles d’assister par voie numérique plutôt qu’en personne en 2021?
Les conférences médicales virtuelles sont en plein essor, mais sont-elles appelées à durer?
En raison de la pandémie survenue l’année dernière, les organisateurs de conférences et les marques de produits médicaux ont dû se précipiter pour trouver une solution afin de limiter les annulations d’importantes conférences médicales. Les plateformes virtuelles qui en ont résulté ont rapidement progressé pour reproduire l’expérience des conférences en personne par des moyens numériques. Si de nombreuses conférences médicales virtuelles ont été couronnées de succès, en termes de forte participation à de nombreux événements importants, tant nationaux qu’internationaux, des questions subsistaient quant à leur capacité à répondre aux besoins des médecins, des autres prestataires de soins de santé et des entreprises pharmaceutiques et de matériel médical qui parrainaient ces événements.
Virtual medical conferences are on the rise, but are they here to stay?
As a result of the pandemic over the past year, conference organizers and medical brands were set scrambling to find a solution to limit cancelations of key medical conferences. Resulting virtual platforms advanced quickly to emulate the face-to-face conference experience through a digital means. While many virtual medical conferences were successful, in terms of strong participation levels to many key events both national and international, questions remained as to how well they met the needs of physicians, other healthcare providers and the pharmaceutical and medical device companies sponsoring these events.
The COVID-19 crisis has significantly impacted physicians’ practices; but how and to what extent? Physicians have been managing significant workloads, while learning on the fly how to navigate and setup virtual meetings. Maintaining high levels of patient care while minimizing in-person interactions has also been challenging.
Physicians recognize that new medications often can be quite valuable for their patients and are eager to add them to their armamentarium. However, they do not always end up prescribing these new medications as much as they initially plan or as early as they would like. There are many reasons that can explain this discrepancy.
In the healthcare system, a patient’s journey to optimal care presents many obstacles. There are numerous steps involved from the onset of a medical condition to the moment when satisfactory results are achieved. This healthcare survey seeks to reveal key opportunities within the patient journey that would assist patients along their way and ultimately improve outcomes. Further healthcare market research could also be conducted by disease area to dig deeper into these insights.
Biological drugs, protein-based products derived from living cells using biotechnology, have been used since the 1990’s as a treatment option for cancer patients. Since 2009, biosimilar therapies (therapeutically equivalent subsequent entry biologics) have been available in different therapeutic areas in Canada, and are now on the verge of becoming available for use in oncology.
Biomarkers are molecules found in bodily fluids or tissues (including the tumor tissue). They provide valuable information about the cancer cells and non-cancer cells when analyzing which biomarkers are produced in response to the cancer. By developing a biomarker profile of a patient’s cancer, doctors can recommend the best suited treatment plan for their patient.
Smart Drugs (or nootropics) are substances used to enhance cognitive functions. Exact usage numbers are difficult to ascertain, but a recent study conducted among UBC students found that 1 in 30 students admitted using ADHD medication they were not prescribed, for their cognitive effects. The use of Smart Drugs appears to be gaining momentum in Canada, especially among students and young professionals in high pressure situations, thereby having the potential to turn into a public health issue.